<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737475</url>
  </required_header>
  <id_info>
    <org_study_id>CA012-004</org_study_id>
    <secondary_id>2015-004816-39</secondary_id>
    <nct_id>NCT02737475</nct_id>
  </id_info>
  <brief_title>An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread</brief_title>
  <official_title>A Phase 1/2a Study of BMS-986178 Administered Alone or in Combination With Nivolumab and/or Ipilimumab in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and tumor-shrinking ability of&#xD;
      experimental medication BMS-986178, when given by itself or in combination with Nivolumab&#xD;
      and/or Ipilimumab, in participants with solid cancers that are advanced or have spread.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 17, 2016</start_date>
  <completion_date type="Actual">November 2, 2020</completion_date>
  <primary_completion_date type="Actual">November 2, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs (adverse events)</measure>
    <time_frame>Approximately 4 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of SAEs (serious adverse events)</measure>
    <time_frame>Approximately 4 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Approximately 4 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of deaths</measure>
    <time_frame>Approximately 4 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinical laboratory test abnormalities - Hematology</measure>
    <time_frame>Approximately 4 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinical laboratory test abnormalities - Chemistry</measure>
    <time_frame>Approximately 4 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinical laboratory test abnormalities - Urinalysis</measure>
    <time_frame>Approximately 4 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinical laboratory test abnormalities - Serology</measure>
    <time_frame>Approximately 4 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum observed serum concentration) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (time of maximum observed concentration) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) (area under the concentration-time curve from time zero to the time) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(TAU) (area under the concentration-time curve in 1 dosing interval) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau (the observed concentration at the end of a dosing interval) for BMS- 986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLT (total body clearance) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css-avg [average concentration over a dosing interval (AUC(TAU)/tau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AI [ratio of an exposure measure at steady state to that after the first dose (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS- 986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-HALFeff [effective elimination half-life to explain degree of accumulation for a specific exposure measure (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough [trough observed plasma concentrations (this includes pre-dose concentrations (C0) and Ctau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessed by number of participants with positive anti-drug antibodies (ADA) to BMS-986178</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessed by number of participants with positive ADA to nivolumab</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity assessed by number of participants with positive ADA to ipilimumab</measure>
    <time_frame>Approximately 100 days after the final study drug administration (end of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants showing a change in one of the pharmacodynamic biomarkers of BMS-986178 dosed in combination with nivo or nivo alone (Part 8) and sustained T cell expansion with DPV-001 in combination with nivo with or without BMS-986178 (Part 9)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>nivo (nivolumab)</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986178 at specified doses at specified intervals&#xD;
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Escalation and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986178 in combination with Nivolumab at specified doses at specified intervals&#xD;
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Dose Escalation and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986178 in combination with Ipilimumab at specified doses at specified intervals&#xD;
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4: Dose Schedule and Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986178/Nivolumab at specified doses at specified intervals&#xD;
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 5: Dose Schedule and Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986178/Ipilimumab at specified doses at specified intervals&#xD;
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 6: Dose Safety and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals&#xD;
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 7: Dose Safety and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986178/Ipilimumab/Nivolumab at specified doses at specified intervals&#xD;
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 8: Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986178/Nivolumab with tetanus vaccine at specified doses and interval&#xD;
Enrollment is closed for this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 9: Dose Exploration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986178/Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 1) at specified doses at specified intervals OR Nivolumab/DPV-001 vaccine/cyclophosphamide (cohort 2) at specified doses at specified intervals&#xD;
Enrollment is open for this arm [Tumor type triple negative breast cancer (TNBC)]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986178</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1: Dose Escalation</arm_group_label>
    <arm_group_label>Part 2: Dose Escalation and Expansion</arm_group_label>
    <arm_group_label>Part 3: Dose Escalation and Expansion</arm_group_label>
    <arm_group_label>Part 4: Dose Schedule and Exploration</arm_group_label>
    <arm_group_label>Part 5: Dose Schedule and Exploration</arm_group_label>
    <arm_group_label>Part 6: Dose Safety and Expansion</arm_group_label>
    <arm_group_label>Part 7: Dose Safety and Expansion</arm_group_label>
    <arm_group_label>Part 8: Dose Exploration</arm_group_label>
    <arm_group_label>Part 9: Dose Exploration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 2: Dose Escalation and Expansion</arm_group_label>
    <arm_group_label>Part 4: Dose Schedule and Exploration</arm_group_label>
    <arm_group_label>Part 6: Dose Safety and Expansion</arm_group_label>
    <arm_group_label>Part 7: Dose Safety and Expansion</arm_group_label>
    <arm_group_label>Part 8: Dose Exploration</arm_group_label>
    <arm_group_label>Part 9: Dose Exploration</arm_group_label>
    <other_name>BMS-936558</other_name>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 3: Dose Escalation and Expansion</arm_group_label>
    <arm_group_label>Part 5: Dose Schedule and Exploration</arm_group_label>
    <arm_group_label>Part 6: Dose Safety and Expansion</arm_group_label>
    <arm_group_label>Part 7: Dose Safety and Expansion</arm_group_label>
    <other_name>BMS-734016</other_name>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tetanus vaccine</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 8: Dose Exploration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DPV-001 vaccine</intervention_name>
    <description>DPV-001 (UbiLT3 and UbiLT6): Specified dose on specified days</description>
    <arm_group_label>Part 9: Dose Exploration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 9: Dose Exploration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        For Part 9 (only arm open for enrollment):&#xD;
&#xD;
          -  Stage IV metastatic or unresectable triple negative breast cancer (TNBC) with zero or&#xD;
             one prior systemic therapies in the advanced metastatic setting&#xD;
&#xD;
          -  Participants with &lt; 12 months from receipt of last curative-intent chemotherapy are&#xD;
             allowed; curative chemotherapy will be considered first-line therapy&#xD;
&#xD;
          -  Prior receipt of chemotherapy in the (neo)adjuvant setting is acceptable, as long as&#xD;
             completed greater than 6 months from start of treatment&#xD;
&#xD;
          -  Tumor biopsy samples (mandatory pre- and on-treatment biopsies) are required for all&#xD;
             participants enrolled&#xD;
&#xD;
          -  Must have histologic or cytologic confirmation of a malignancy that is advanced&#xD;
             (metastatic, recurrent, refractory, and/or unresectable) with measurable disease per&#xD;
             Response Evaluation Criteria in Solid Tumors (RECIST) v1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1&#xD;
&#xD;
          -  Men and women must agree to follow specific methods of contraception, if applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Must be immunotherapy treatment naïve, including no prior therapy with T cell immune&#xD;
             checkpoint blocker (anti-PDL1, anti-PD1). Prior receipt of intralymphatic cytokine&#xD;
             therapy (IRX-2) is acceptable (Part 9 only)&#xD;
&#xD;
          -  Other active malignancy requiring concurrent intervention&#xD;
&#xD;
          -  Prior therapy with any agent specifically targeting T-cell co-stimulation pathways&#xD;
             such as anti-OX40 antibody, anti-CD137, anti- glucocorticoid-induced TNFR-related gene&#xD;
             (anti-GITR) antibody, and anti-CD27&#xD;
&#xD;
          -  Known or underlying medical or psychiatric condition and/or social reason that, in the&#xD;
             opinion of the investigator or Sponsor, could make the administration of study drug&#xD;
             hazardous to the participant or could adversely affect the ability of the participant&#xD;
             to comply with or tolerate the study&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Cumc)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale Tumori Milano</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Univ. Vall dHebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28049</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Puerta De Hierro</name>
      <address>
        <city>Majadahonda - Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen De La Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 2, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

